Search Our Website:
Sep 21 2020
1:15 PM

Edward John Allera, co-chair of the firm's FDA group, and Matthew Fedowitz, shareholder in the firm's Intellectual Property section, will present Key Business and IP Considerations for Furthering Drug Repurposing Programs for the 9th Annual Repositioning, Repurposing and Rescue Conference.

The presentation will cover the following:

  • Increasing the value of your 505(b)(2)
  • Dealing with CMS actions that increase the value of independent 505(b)(2)s
  • Monitoring FDA and Congress for the impact of user fees on 505(b)(2)s
  • Assessing the impact of Executive Orders on 505(b)2()s